Reconciling the gap in global health issues happens when institutions recognize that they cannot work alone. Partnerships with domestic and international organizations to share global health objectives will improve collective knowledge and data and therefore, aid in analyzing worldwide trends. The goal of these partnerships is to promote research and development, drive new policies, establish new programs, and contribute to a holistic understanding of global health threats.
The session “Public & Private Partnerships in Support of Global Health” at GTCbio’s Infectious Diseases Summit will be showcasing the following speakers from institutes/companies that will discuss the types and availability of economic incentives to spur innovation and therapy development for global health. This summit will be held at the Royal Sonesta Harbor Court Baltimore on July 13-14, 2017 in Baltimore, MD.
• Tyler Merkeley, Project Officer, BARDA, HHS
Tyler Merkeley will recap the first year of CARB-X and discuss their vision for Year #2 as they continue to build a Global Innovation Fund to accelerate global antibacterial innovation to address the threat of antibiotic resistant infections.
• Jean-Pierre Paccaud, Director, Business Development, Global Antibiotic R&D Partnership (GARDP)
Initiated and incubated through close collaboration between WHO and Drugs for Neglected Diseases initiative (DNDi), GARDP’s mission is to work in partnership with the public and private sectors to develop and deliver new treatments for bacterial infections wherever drug resistance is present or emerging, or for which inadequate treatment exists, and where it is unlikely that they will be developed by the private sector.
• Kevin Gilligan, Senior Scientific Advisor, ClinicalRM
Kevin J. Gilligan is a virologist and emerging disease expert with over 30 years of experience in academia, government and industry developing vaccines, drugs and diagnostics to address public health issues related to global emerging disease.
• Joseph Larsen, Deputy Director, CBRN Medical Countermeasures, BARDA, HHS
Joseph Larsen will focus on BARDA’s strategy, its major programs/initiatives, and discuss current gaps in BARDA’s ability to incentivize industry to develop medical countermeasures for national defense, emerging infectious diseases, and antibiotic resistant bacteria.
We invite you to join us at GTCbio’s Infectious Diseases Summit, which consists of three co-located conferences:
I. 15th Vaccines Research & Development will focus on defining emerging global health threats (Zika, multi-drug resistant TB, influenza), discussing next generation technologies to address these foes (novel adjuvants, DC vaccines, nucleic acid vaccines, recombinant viral vectors) and addressing challenges to those goals.
II. 14th Anti-Infectives Partnering & Deal-Making: highlights the types and availability of economic incentives to spur innovation and development of therapies to address rapidly emerging global health threats, international partnering and funding opportunities, and non-traditional approaches and technologies, including innovative clinical trial strategies for the development of anti-infectives.
III. 6th Antiviral Drugs Research & Development emphasizes current landscape and emerging new therapies in the field of HIV, RSV, Hepatitis B/C, Influenza etc. New drug designs and their mechanism of actions, approaches to address immune evasion mechanisms and viral resistance, and challenges in clinical study designs will also be discussed.